Avastin: payments to doctors
Payments that named Avastin as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $45.2M
- Providers
- 3,059
- Transactions
- 6,793
- Average per transaction
- $6,652
The per-transaction average — $6,652 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 3,059 providers the average total is $14,771, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech, Inc. | $43,390,195 | 96.0% |
| Genentech USA, Inc. | $1,510,897 | 3.3% |
| Chugai Pharmaceutical Co., Ltd. | $134,377 | 0.3% |
| F. Hoffmann-la Roche AG | $104,940 | 0.2% |
| Amneal Pharmaceuticals LLC | $22,486 | 0.0% |
| Roche Products Limited | $11,599 | 0.0% |
| Hoffmann-la Roche Limited | $10,025 | 0.0% |